Efficacy and safety of ciprofol for the sedation/anesthesia in patients undergoing hysteroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059674

Enrollment

Unknown

Registered

2022-05-06

Start date

2022-05-01

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopic anesthesia

Interventions

Treatment:Ciprofol

Control:Propofol

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the standard of hysteroscopic surgery; 2. ASA is classified as I II; 3. Volunteer to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergies to propofol, remifentanil and other drugs; 2. ASA classification = Level III; 3. Suffering from mental illness that has been treated with drugs for a long time; 4. Pregnancy or lactation; 5. Incomplete clinical data; 6. Have taken opiates or sedatives within one week; 7. Have participated in clinical trials of other drugs in the past 4 weeks.

Design outcomes

Primary

Measure	Time frame
success rate;	—

Secondary

Measure	Time frame
Recovery time;The top-up dosing times and dosage of ciprofol and/or propofol for maintaining adequate sedation/anesthesia;	—

Countries

China

Contacts

Public ContactBin Qian

Yancheng First People's Hospital

985578655@qq.com+86 13951489138

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026